Denali Therapeutics Inc. Common Stock (DNLI) Financials
Key financial figures for Denali Therapeutics Inc. Common Stock (Q2 2026).
- Revenue
- $4M
- Net Income
- -$128M
- EPS
- $-0.68
- Total Assets
- $1.2B
- Operating Cash Flow
- -$97M
Full income statement, balance sheet, and cash flow for Denali Therapeutics Inc. Common Stock on SentiSense.